Jimmy Van den Eynden | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/jimmy-van-den-eynden/Jimmy Van den EyndenHugo Blox Builder (https://hugoblox.com)en-usFri, 17 Apr 2026 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngJimmy Van den Eyndenhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/jimmy-van-den-eynden/RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/ruvbl1_ruvbl2_neuroblastoma/Fri, 17 Apr 2026 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/ruvbl1_ruvbl2_neuroblastoma/Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactionshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Wed, 01 Oct 2025 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/spatial_transcriptomics_neuroblastoma/Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEANhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/clean/Thu, 11 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/clean/ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibitionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/Tue, 02 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri2/ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expressionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Tue, 21 Feb 2023 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLChttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/Thu, 01 Sep 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/ATR inhibition enables complete tumour regression in ALK-driven NB mouse modelshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/Wed, 24 Nov 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/atri1/Loss of RET Promotes Mesenchymal Identity in Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/loss_ret/Thu, 15 Apr 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/loss_ret/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastomahttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/Tue, 22 Sep 2020 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwayshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Tue, 20 Nov 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/Wed, 01 Aug 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_i1171t/